Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 5 de 5
1.
J Cell Mol Med ; 25(22): 10663-10673, 2021 11.
Article En | MEDLINE | ID: mdl-34698450

The proliferation of pulmonary artery smooth muscle cells (PASMCs) is an important cause of pulmonary vascular remodelling in hypoxia-induced pulmonary hypertension (HPH). However, its underlying mechanism has not been well elucidated. Connexin 43 (Cx43) plays crucial roles in vascular smooth muscle cell proliferation in various cardiovascular diseases. Here, the male Sprague-Dawley (SD) rats were exposed to hypoxia (10% O2 ) for 21 days to induce rat HPH model. PASMCs were treated with CoCl2 (200 µM) for 24 h to establish the HPH cell model. It was found that hypoxia up-regulated the expression of Cx43 and phosphorylation of Cx43 at Ser 368 in rat pulmonary arteries and PASMCs, and stimulated the proliferation and migration of PASMCs. HIF-1α inhibitor echinomycin attenuated the CoCl2 -induced Cx43 expression and phosphorylation of Cx43 at Ser 368 in PASMCs. The interaction between HIF-1α and Cx43 promotor was also identified using chromatin immunoprecipitation assay. Moreover, Cx43 specific blocker (37,43 Gap27) or knockdown of Cx43 efficiently alleviated the proliferation and migration of PASMCs under chemically induced hypoxia. Therefore, the results above suggest that HIF-1α, as an upstream regulator, promotes the expression of Cx43, and the HIF-1α/Cx43 axis regulates the proliferation and migration of PASMCs in HPH.


Connexin 43/metabolism , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Myocytes, Smooth Muscle/metabolism , Animals , Cell Proliferation , Cells, Cultured , Connexin 43/agonists , Connexin 43/genetics , Hypoxia/genetics , Hypoxia/metabolism , Immunohistochemistry , Models, Biological , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/metabolism , Phosphorylation , Promoter Regions, Genetic , Protein Binding , Pulmonary Artery/cytology , Pulmonary Artery/metabolism , Rats
2.
Biomolecules ; 10(11)2020 11 20.
Article En | MEDLINE | ID: mdl-33233647

In epilepsy research, emphasis is put on exploring non-neuronal targets such as astrocytic proteins, since many patients remain pharmacoresistant to current treatments, which almost all target neuronal mechanisms. This paper reviews available data on astrocytic connexin43 (Cx43) signaling in seizures and epilepsy. Cx43 is a widely expressed transmembrane protein and the constituent of gap junctions (GJs) and hemichannels (HCs), allowing intercellular and extracellular communication, respectively. A plethora of research papers show altered Cx43 mRNA levels, protein expression, phosphorylation state, distribution and/or functional coupling in human epileptic tissue and experimental models. Human Cx43 mutations are linked to seizures as well, as 30% of patients with oculodentodigital dysplasia (ODDD), a rare genetic condition caused by mutations in the GJA1 gene coding for Cx43 protein, exhibit neurological symptoms including seizures. Cx30/Cx43 double knock-out mice show increased susceptibility to evoked epileptiform events in brain slices due to impaired GJ-mediated redistribution of K+ and glutamate and display a higher frequency of spontaneous generalized chronic seizures in an epilepsy model. Contradictory, Cx30/Cx43 GJs can traffic nutrients to high-energy demanding neurons and initiate astrocytic Ca2+ waves and hyper synchronization, thereby supporting proconvulsant effects. The general connexin channel blocker carbenoxolone and blockers from the fenamate family diminish epileptiform activity in vitro and improve seizure outcome in vivo. In addition, interventions with more selective peptide inhibitors of HCs display anticonvulsant actions. To conclude, further studies aiming to disentangle distinct roles of HCs and GJs are necessary and tools specifically targeting Cx43 HCs may facilitate the search for novel epilepsy treatments.


Astrocytes/cytology , Connexin 43/genetics , Connexin 43/metabolism , Epilepsy/drug therapy , Animals , Astrocytes/drug effects , Connexin 43/agonists , Connexin 43/antagonists & inhibitors , Epilepsy/genetics , Epilepsy/metabolism , Gap Junctions/drug effects , Gap Junctions/metabolism , Humans , Peptides/pharmacology , Peptides/therapeutic use , Seizures/drug therapy , Seizures/genetics , Seizures/metabolism
3.
Reprod Biol Endocrinol ; 12: 90, 2014 Sep 20.
Article En | MEDLINE | ID: mdl-25239217

BACKGROUND: Aromatase converts testosterone into 17beta-estradiol in granulosa cells, and the converted 17beta-estradiol contributes to follicular maturation. Additionally, excessive testosterone inhibits aromatase activity, which can lead to concerns regarding polycystic ovary syndrome (PCOS). Generally, 1,25-dihydroxyvitamin D3 (1,25D3) supplements help to improve the symptoms of PCOS patients who exhibit low blood levels of 1,25D3. Therefore, this study investigated the interaction effects of 1,25D3 and testosterone on estrogenesis and intercellular connections in rat granulosa cells. METHODS: Primary cultures of granulosa cells were treated with testosterone or testosterone plus 1,25D3, or pre-treated with a calcium channel blocker or calcium chelator. Cell lysates were subjected to western blot analysis to determine protein and phosphorylation levels, and 17beta-estradiol secretion was examined using a radioimmunoassay technique. Cell viability was evaluated by MTT reduction assay. Connexin 43 (Cx43) mRNA and protein expression levels were assessed by qRT-PCR, western blot, and immunocytochemistry. RESULTS: Testosterone treatment (0.1 and 1 microg/mL) increased aromatase expression and 17beta-estradiol secretion, and the addition of 1,25D3 attenuated testosterone (1 microg/mL)-induced aromatase expression but improved testosterone-induced 17beta-estradiol secretion. Furthermore, testosterone-induced aromatase phosphotyrosine levels increased at 10 min, 30 min and 1 h, whereas 1,25D3 increased the longevity of the testosterone effect to 6 h and 24 h. Within 18-24 h of treatment, 1,25D3 markedly enhanced testosterone-induced 17beta-estradiol secretion. Additionally, pre-treatment with a calcium channel blocker nifedipine or an intracellular calcium chelator BAPTA-AM reduced 1,25D3 and testosterone-induced 17beta-estradiol secretion. Groups that underwent testosterone treatment exhibited significantly increased estradiol receptor beta expression levels, which were not affected by 1,25D3. Neither testosterone nor 1,25D3 altered 1,25D3 receptor expression. Finally, at high doses of testosterone, Cx43 protein expression was decreased in granulosa cells, and this effect was reversed by co-treatment with 1,25D3. CONCLUSIONS: These data suggest that 1,25D3 potentially increases testosterone-induced 17beta-estradiol secretion by regulating aromatase phosphotyrosine levels, and calcium increase is involved in both 1,25D3 and testosterone-induced 17beta-estradiol secretion. 1,25D3 reverses the inhibitory effect of testosterone on Cx43 expression in granulosa cells.


Calcitriol/metabolism , Connexin 43/metabolism , Estradiol/metabolism , Gene Expression Regulation, Developmental , Granulosa Cells/metabolism , Testosterone/metabolism , Up-Regulation , Animals , Aromatase/chemistry , Aromatase/metabolism , Calcium Channel Blockers/pharmacology , Calcium Chelating Agents/pharmacology , Calcium Signaling/drug effects , Cells, Cultured , Connexin 43/agonists , Connexin 43/antagonists & inhibitors , Connexin 43/genetics , Down-Regulation/drug effects , Estradiol/agonists , Estradiol/chemistry , Estrogen Antagonists/pharmacology , Female , Gene Expression Regulation, Developmental/drug effects , Granulosa Cells/cytology , Granulosa Cells/drug effects , Phosphorylation/drug effects , Protein Processing, Post-Translational/drug effects , Rats, Sprague-Dawley , Receptors, Estradiol/agonists , Receptors, Estradiol/antagonists & inhibitors , Receptors, Estradiol/metabolism , Testosterone/agonists , Testosterone/antagonists & inhibitors , Up-Regulation/drug effects
4.
Expert Opin Ther Targets ; 14(7): 681-92, 2010 Jul.
Article En | MEDLINE | ID: mdl-20446866

IMPORTANCE OF THE FIELD: Connexins (Cxs) and gap junctional intercellular communications (GJICs) play roles in cancer development, growth and metastasis. Experimental studies suggest that targeting Cxs may be a novel technique, either to inhibit tumor cell growth directly or to sensitize to various therapies. AREAS COVERED IN THIS REVIEW: A brief introduction to the role of Cxs in cancer. The focus is mainly on data available in the literature regarding therapeutic aspects. WHAT THE READER WILL GAIN: This article reviews the various strategies that take advantage of gap junctions and connexins to eliminate cancer cells, including use of the bystander effect (BE) in gene therapy, the effect of connexins on chemosensitization, the role of apoptotic processes and interactions with the microenvironment. Attempts to restore connexin expression at the transcriptional and post-transcriptional levels are described, as well as promising strategies recently explored. The potential and limitations of the approaches are discussed. TAKE HOME MESSAGE: Connexins have multiple facets, singly, in hemichannel complexes, in gap junctions or interacting with different proteins. The regulation of their expression is not fully resolved and selective manipulation of Cxs expression is therefore a challenge. Although the therapeutic potential of connexins is undeniable, more effort is needed to study the regulation and functions of these proteins.


Cell Communication/drug effects , Connexins/physiology , Gap Junctions/drug effects , Gap Junctions/physiology , Neoplasms/drug therapy , Animals , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Apoptosis/physiology , Biomarkers, Tumor/metabolism , Bystander Effect/drug effects , Cell Communication/physiology , Connexin 43/agonists , Connexin 43/antagonists & inhibitors , Connexin 43/metabolism , Connexins/agonists , Connexins/genetics , Gene Expression Regulation, Neoplastic/drug effects , Genetic Therapy , Humans , MicroRNAs/physiology , Neoplasm Metastasis/drug therapy , Neoplasm Metastasis/physiopathology , Neoplasms/metabolism , Neoplasms/physiopathology , Neoplasms/therapy , Protein Processing, Post-Translational/drug effects
5.
Int J Biochem Cell Biol ; 38(10): 1642-6, 2006.
Article En | MEDLINE | ID: mdl-16677845

Connexins, that have their main function as part of gap junction channels, are proteins expressed in a large number of tissues such as endocrine, nervous, vascular, and muscular tissues. Gap junctions are implicated in tissue homeostasis and control of cell proliferation and differentiation. Interestingly, mutations of connexin genes have been reported in several human diseases (peripheral neuropathies, cardiovascular and dermatological diseases, hereditary cataract, and deafness) and altered expression of connexins have been associated with tumoral progression. Today, several lines of study argue for a critical role of gap junctions in corporal smooth muscle relaxation and erectile response. The present review highlights the emerging role of connexin43, one of these membranous proteins, in the physiology and physiopathology of human erectile function and its possible medical application.


Connexin 43/physiology , Erectile Dysfunction/metabolism , Erectile Dysfunction/therapy , Penile Erection , Connexin 43/agonists , Connexin 43/genetics , Erectile Dysfunction/genetics , Gap Junctions/metabolism , Humans , Male , Penile Erection/genetics , Protein Conformation
...